A-319 / ITabMed - LARVOL DELTA

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Wuhan Union Hospital, China | N=18 ➔ 25

Enrollment change • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity (ACR Convergence 2024) - P1 | "DAS-28 CRP score improved from 5.83 at BL to 1.96 at W2 in Pt 002, while Pt 003 showed improvement of SLE-related vasculitis by W2 (Fig. A-319 is well tolerated in severe/refractory SLE pts without evidence of CRS, ICANS or other safety issues commonly seen in T cell-mediated B cell depletion therapies. A-319 (0.05 + 0.3μg/kg) treatment demonstrated rapid B cell depletion, autoantibody reduction, and organ function improvement as early as W2. Evidence of partial B cell recovery was seen by W2."

Late-breaking abstract • CNS Disorders • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Oncology • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Wuhan Union Hospital, China | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Wuhan Union Hospital, China

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2023) - P1 | "A-319 has the same mechanism of action as that of blinatumomab, and may benefit B-NHL patients. A-319 was well tolerated in relapsed/refractory B-NHL. A-319 at the dose level of 1. 2 ug/kg/day showed encouraging disease control and warranted further clinical investigation."

Clinical • Cardiovascular • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Interstitial Lung Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Pulmonary Embolism • Respiratory Diseases

The closest lineage of Archaeplastida is revealed by phylogenomics analyses that include Microheliella maris. (PubMed, Open Biol) - "In this study, we analysed a 319-gene alignment and demonstrated that M. maris represents a basal lineage of one of the major eukaryotic lineages, Cryptista...The 319-gene analyses also indicated that M. maris is a key taxon to recover the monophyly of Archaeplastida and the sister relationship between Archaeplastida and Pancryptista, which is collectively called 'CAM clade' here. Significantly, Cryptophyceae tend to be attracted to Rhodophyta depending on the taxon sampling (ex., in the absence of M. maris and Rhodelphidia) and the particular phylogenetic 'signal' most likely hindered the stable recovery of the monophyly of Archaeplastida in previous studies."

Journal

Misinformation Warnings: Twitter's Soft Moderation Effects on COVID-19 Vaccine Belief Echoes. (PubMed, Comput Secur) - "We conducted a 319-participants study with both verified and misleading Tweets covered or tagged with the COVID-19 misinformation warnings to investigate how Twitter users perceive the accuracy of COVID-19 vaccine content on Twitter...These "belief echoes" manifested as skepticism of adequate COVID-19 immunization particularly among Republicans and Independents as well as female Twitter users. Surprisingly, we found that the belief echoes are strong enough to preclude adult Twitter users to receive the COVID-19 vaccine regardless of their education level."

Journal • Infectious Disease • Novel Coronavirus Disease

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia. (PubMed, Front Med) - "The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. The two molecules are complementary in terms of efficacy and specificity profile. The activity of A-319 demonstrated superior to that of A-2019, whereas A-2019 has an additional capability to target CD20 in cells missing CD19, suggesting its potential function against CD19 weak or negative CD20 positive leukemic cells."

Journal • Preclinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

[VIRTUAL] THE CD19/CD3 BISPECIFIC ANTIBODY WORK EFFECTIVELY AS ADJUNCT WITH IBRUTINIB ON THE TREATMENT OF B-CELL LYMPHOMA (ICML 2021) - "Blinatumomab as the first generation CD19/CD3 bispecific antibody (bsAb) was approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. We found that A-319 could greatly activate T cells and promote the proliferation of T cells from patients. The addition of ibrutinib effectively enhanced the anti-tumor effects and lower the CRS of A-319 possibly through the regulation of macrophage mediated angiogenesis."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD163 • CD34 • CD69 • CD86 • IL2 • IL2RA

"Finnair to dismantle and recycle an A319 aircraft at Helsinki Airport https://t.co/UhLKEoImkM" (@CisionNews)

Non-basic amino acids in the hemagglutinin proteolytic cleavage site of a European H9N2 avian influenza virus modulate virulence in turkeys. (PubMed, Sci Rep) - "Recombinant viruses carrying single HACS mutations resembling field viruses were constructed (designated G319, A319, N319, S319, D319 and K319)...Therefore, the silent circulation of potentially zoonotic H9N2 viruses in poultry should be monitored carefully. These results are important for understanding the adaptation of H9N2 in poultry and replication in mammalian cells."

Journal • Infectious Disease • Respiratory Diseases

Day-to-Day Variability of Walking Performance Measures in Individuals Poststroke and Individuals With Parkinson Disease. (PubMed, J Neurol Phys Ther) - "The results of this study elucidate the factors that are related to and predict day-to-day variability of performance. Walking performance metrics should be evaluated over multiple days and greater variability should be anticipated with greater amounts of performance.Video Abstract available: for more insights from the authors (see the Video, Supplemental Digital Content 1, available at: http://links.lww.com/JNPT/A319)."

Clinical • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1; N=54; Not yet recruiting; Sponsor: Generon (Shanghai) Corporation Ltd.

New P1 trial